Detalhe da pesquisa
1.
A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis.
Int J Rheum Dis
; 23(7): 876-881, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32476277
2.
Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial.
BioDrugs
; 34(2): 197-207, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31939063
3.
Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis.
Expert Opin Biol Ther
; 19(10): 1065-1074, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31284794
4.
The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product.
Therap Adv Gastroenterol
; 12: 1756284819852535, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31223341
5.
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
Arthritis Res Ther
; 20(1): 155, 2018 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30053896
6.
A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01).
Expert Rev Clin Immunol
; 14(4): 329-336, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29504427
7.
CD8 alpha beta T cells are not essential to the pathogenesis of arthritis or colitis in HLA-B27 transgenic rats.
J Immunol
; 170(2): 1099-105, 2003 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12517979